Remibrutinib for Chronic Urticaria
(REMIX-1 Trial)
Recruiting in Palo Alto (17 mi)
+144 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 3
Waitlist Available
Sponsor: Novartis Pharmaceuticals
Pivotal Trial (Near Approval)
Prior Safety Data
Breakthrough Therapy
Trial Summary
What is the purpose of this trial?
This trial is testing a new medication called remibrutinib to help adults with chronic hives that don't improve with standard allergy medicines. The medication works by blocking signals in the body that cause inflammation and allergic reactions. Remibrutinib has shown promising results in treating chronic spontaneous urticaria.
Research Team
NP
Novartis Pharmaceuticals
Principal Investigator
Novartis Pharmaceuticals
Eligibility Criteria
Adults over 18 with chronic spontaneous urticaria (CSU) not well-managed by H1-antihistamines can join this trial. They must have had CSU for at least 6 months, experience itch and hives despite current treatment, and be able to keep a daily diary of their symptoms. People with other skin conditions or diseases causing similar symptoms, significant bleeding risks, or severe health issues like heart disease are excluded.Inclusion Criteria
You have had chronic hives for at least 6 months before the screening.
You have been experiencing itchiness and hives for at least 6 weeks, even though you have been taking a certain type of antihistamine.
You must be 18 years old or older to participate.
See 6 more
Exclusion Criteria
You have other medical conditions that cause hives or swelling, like urticaria vasculitis, erythema multiforme, or mastocytosis.
You have a specific cause for your chronic hives, such as from physical triggers like pressure, cold, heat, or water.
You need to take blood-thinning medication like warfarin or NOACs.
See 6 more
Treatment Details
Interventions
- LOU064 (Bruton's Tyrosine Kinase (BTK) Inhibitor)
- Placebo (Drug)
Trial OverviewThe trial is testing the effectiveness of Remibrutinib (LOU064), an investigational drug for CSU against a placebo. Participants will either receive the study drug in blinded conditions or open-label after initial phases, while their responses are compared to those receiving a non-active pill.
Participant Groups
2Treatment groups
Experimental Treatment
Placebo Group
Group I: LOU064 25mg b.i.d.Experimental Treatment2 Interventions
Patients initially randomized to Remibrutinib during the Double-blind treatment period and continued Remibrutinib during the Open-label treatment period (Up to Week 52)
Group II: PlaceboPlacebo Group2 Interventions
Patients initially randomized to Placebo (Up to Week 24)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novartis Pharmaceuticals
Lead Sponsor
Trials
2,963
Recruited
4,275,000+
Founded
1996
Headquarters
Basel, Switzerland
Known For
Precision medicine
Top Products
Gleevec, Cosentyx, Entresto, Kisqali
Dr. Vas Narasimhan
Novartis Pharmaceuticals
Chief Executive Officer since 2018
MD from Harvard Medical School
Dr. Shreeram Aradhye
Novartis Pharmaceuticals
Chief Medical Officer since 2021
MD